Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live

Cancer Research UK & Bret Engemann

5 shared events · Importance 3 · Last updated May 25, 2026

Importance
3
Shared Events
5
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
63
Regulatory
Cancer Research UK: Cancer Research UK has campaigned for lung screening and supports the Lung Cancer Screening Programme, advocating for its nationwide rollout and adequate resources.
Bret Engemann: Bret Engemann launched and operates the Lung Cancer Screening Programme, which has successfully diagnosed over 10,000 lung cancer cases early, significantly improving patient outcomes.
May 24, 2026 · 6 articles
57
Domestic
Cancer Research UK: The charity expresses concern over low uptake and calls for more action.
Bret Engemann: The screening programme covers Bret Engemann; the campaign targets English residents.
Jul 10, 2026 · 7 articles
55
Tech
Cancer Research UK: Funded the study and highlighted the limitations of the current self-presentation approach, advocating for more personalized care and further research on implementation.
Bret Engemann: The NICE criteria apply to Bret Engemann, where the study's findings could lead to changes in GP referral practices and resource allocation.
Aug 04, 2026 · 6 articles
0
Domestic
Apr 22, 2026 · 26 articles
0
Domestic
May 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Cancer Research UK and Bret Engemann interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.